Heart failure-related pleural effusion: determinants of pleural drainage and predictors of mortality in a cohort of 1372 patients.

IF 4.4 3区 医学 Q1 RESPIRATORY SYSTEM
ERJ Open Research Pub Date : 2026-10-26 eCollection Date: 2026-09-01 DOI:10.1183/23120541.01853-2025
José M Porcel, Alena Belokopytova, Juan C Pineda, Laura Porcel, Silvia Bielsa
{"title":"Heart failure-related pleural effusion: determinants of pleural drainage and predictors of mortality in a cohort of 1372 patients.","authors":"José M Porcel, Alena Belokopytova, Juan C Pineda, Laura Porcel, Silvia Bielsa","doi":"10.1183/23120541.01853-2025","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) is one of the most common causes of pleural effusion, yet data on its management and prognosis in patients undergoing diagnostic thoracentesis are limited. The significance of invasive pleural interventions remains uncertain.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of a prospectively maintained pleural database, including consecutive patients with HF-related pleural effusion who underwent diagnostic thoracentesis. Clinical characteristics, pleural findings, need for invasive pleural management (therapeutic thoracentesis or indwelling pleural catheter (IPC)), and mortality were assessed. Fine-Gray competing-risk models and Cox regression were applied.</p><p><strong>Results: </strong>A total of 1372 patients were included (median age 85 years). During follow-up, 726 (53%) patients required at least one therapeutic thoracentesis and 81 (6%) received an IPC. In the competing-risk analysis, effusion size equal to or more than half hemithorax (sudistribution hazard ratio (sHR) 2.33), bilateral effusion (sHR 1.37), pleural fluid albumin >1.2 g·dL<sup>-1</sup> (sHR 1.23), and male sex (sHR 1.20) were independently associated with invasive pleural management. Median survival was 14 months, with mortality rates of 50% at 1 year and 70% at 2 years. Mortality was independently associated with advanced age, elevated serum N-terminal pro-brain natriuretic peptide, renal dysfunction, and hypoalbuminemia, whereas pleural characteristics and invasive pleural management were not.</p><p><strong>Conclusion: </strong>In patients with HF-related pleural effusion undergoing diagnostic thoracentesis, mortality is high and primarily driven by systemic markers of advanced HF. Invasive pleural interventions are frequently required in patients with large or bilateral effusions. In descriptive comparisons, survival was similar regardless of pleural intervention status, although causal inference is precluded by the observational design and time-dependent nature of intervention.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13699366/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ERJ Open Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1183/23120541.01853-2025","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Heart failure (HF) is one of the most common causes of pleural effusion, yet data on its management and prognosis in patients undergoing diagnostic thoracentesis are limited. The significance of invasive pleural interventions remains uncertain.

Methods: We conducted a retrospective analysis of a prospectively maintained pleural database, including consecutive patients with HF-related pleural effusion who underwent diagnostic thoracentesis. Clinical characteristics, pleural findings, need for invasive pleural management (therapeutic thoracentesis or indwelling pleural catheter (IPC)), and mortality were assessed. Fine-Gray competing-risk models and Cox regression were applied.

Results: A total of 1372 patients were included (median age 85 years). During follow-up, 726 (53%) patients required at least one therapeutic thoracentesis and 81 (6%) received an IPC. In the competing-risk analysis, effusion size equal to or more than half hemithorax (sudistribution hazard ratio (sHR) 2.33), bilateral effusion (sHR 1.37), pleural fluid albumin >1.2 g·dL-1 (sHR 1.23), and male sex (sHR 1.20) were independently associated with invasive pleural management. Median survival was 14 months, with mortality rates of 50% at 1 year and 70% at 2 years. Mortality was independently associated with advanced age, elevated serum N-terminal pro-brain natriuretic peptide, renal dysfunction, and hypoalbuminemia, whereas pleural characteristics and invasive pleural management were not.

Conclusion: In patients with HF-related pleural effusion undergoing diagnostic thoracentesis, mortality is high and primarily driven by systemic markers of advanced HF. Invasive pleural interventions are frequently required in patients with large or bilateral effusions. In descriptive comparisons, survival was similar regardless of pleural intervention status, although causal inference is precluded by the observational design and time-dependent nature of intervention.

心衰相关胸腔积液:1372例患者胸腔引流的决定因素和死亡率的预测因素
背景:心力衰竭(HF)是胸腔积液最常见的原因之一,但诊断性胸腔穿刺患者的处理和预后数据有限。有创胸膜介入治疗的意义尚不明确。方法:我们对前瞻性维持的胸膜数据库进行了回顾性分析,包括连续接受诊断性胸腔穿刺术的hf相关胸腔积液患者。评估临床特征、胸膜表现、有创胸膜处理(治疗性胸腔穿刺或留置胸膜导管(IPC))的必要性以及死亡率。采用细灰色竞争风险模型和Cox回归。结果:共纳入1372例患者(中位年龄85岁)。在随访期间,726例(53%)患者需要至少一次治疗性胸穿刺,81例(6%)患者接受了IPC。在竞争风险分析中,积液大小等于或超过一半半胸(亚分布风险比(sHR) 2.33)、双侧积液(sHR 1.37)、胸膜液白蛋白>1.2 g·dL-1 (sHR 1.23)和男性(sHR 1.20)与侵入性胸膜治疗独立相关。中位生存期为14个月,1年死亡率为50%,2年死亡率为70%。死亡率与高龄、血清n端前脑利钠肽升高、肾功能不全和低白蛋白血症独立相关,而胸膜特征和侵入性胸膜处理与此无关。结论:在接受诊断性胸腔穿刺的HF相关胸腔积液患者中,死亡率很高,主要由晚期HF的全身标志物驱动。对于大量或双侧积液的患者,侵入性胸膜介入治疗是经常需要的。在描述性比较中,生存率与胸膜干预状态无关,尽管观察设计和干预的时间依赖性排除了因果推断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ERJ Open Research
ERJ Open Research Medicine-Pulmonary and Respiratory Medicine
CiteScore
6.20
自引率
4.30%
发文量
273
审稿时长
8 weeks
期刊介绍: ERJ Open Research is a fully open access original research journal, published online by the European Respiratory Society. The journal aims to publish high-quality work in all fields of respiratory science and medicine, covering basic science, clinical translational science and clinical medicine. The journal was created to help fulfil the ERS objective to disseminate scientific and educational material to its members and to the medical community, but also to provide researchers with an affordable open access specialty journal in which to publish their work.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书